Human endogenous retroviruses (HERVs) associated with glioblastoma risk and prognosis.

Saved in:
Bibliographic Details
Title: Human endogenous retroviruses (HERVs) associated with glioblastoma risk and prognosis.
Authors: Mazumder H; Biostatistics Program, Louisiana State University Health Sciences Center, School of Public Health, New Orleans, LA, USA., Lin HY; Biostatistics Program, Louisiana State University Health Sciences Center, School of Public Health, New Orleans, LA, USA.; Louisiana Cancer Research Center, New Orleans, LA, USA., Baddoo M; Tulane Cancer Center, Tulane Health Sciences Center, New Orleans, LA, USA., Gałan W, Polania-Villanueva D; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA., Hicks C; Department of Genetics and the Bioinformatics and Genomics Program, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA, USA., Otohinoyi D; Department of Genetics and the Bioinformatics and Genomics Program, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA, USA., Peruzzi F; Louisiana Cancer Research Center, New Orleans, LA, USA.; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.; Department of Medicine, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA, USA., Madeja Z; Department of Cell Biology, Jagiellonian University in Kraków, Faculty of Biochemistry, Biophysics and Biotechnology, Kraków, Poland., Belancio VP; Louisiana Cancer Research Center, New Orleans, LA, USA.; Tulane Cancer Center, Tulane Health Sciences Center, New Orleans, LA, USA.; Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA., Flemington EK; Louisiana Cancer Research Center, New Orleans, LA, USA.; Tulane Cancer Center, Tulane Health Sciences Center, New Orleans, LA, USA.; Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA, USA., Reiss K; Louisiana Cancer Research Center, New Orleans, LA, USA.; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA, USA., Rak M; Louisiana Cancer Research Center, New Orleans, LA, USA. mrak1@lsuhsc.edu.; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA. mrak1@lsuhsc.edu.; Department of Cell Biology, Jagiellonian University in Kraków, Faculty of Biochemistry, Biophysics and Biotechnology, Kraków, Poland. mrak1@lsuhsc.edu.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA, USA. mrak1@lsuhsc.edu.
Source: Cancer gene therapy [Cancer Gene Ther] 2025 Jun; Vol. 32 (6), pp. 622-632. Date of Electronic Publication: 2025 May 19.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5500 (Electronic) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5500
DOI:10.1038/s41417-024-00868-3